Document Detail


CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function.
MedLine Citation:
PMID:  20361197     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Inhibition of the cannabinoid receptor CB(1) (CB(1)-R) exerts numerous positive cardiovascular effects such as modulation of blood pressure, insulin sensitivity and serum lipid concentrations. However, direct vascular effects of CB(1)-R inhibition remain unclear. CB(1)-R expression was validated in vascular smooth muscle cells (VSMCs) and aortic tissue of mice. Apolipoprotein E-deficient (ApoE-/-) mice were treated with cholesterol-rich diet and the selective CB(1)-R antagonist rimonabant or vehicle for 7 weeks. CB(1)-R inhibition had no effect on atherosclerotic plaque development, collagen content and macrophage infiltration but led to improved aortic endothelium-dependent vasodilation and decreased aortic reactive oxygen species (ROS) production and NADPH oxidase activity. Treatment of cultured VSMC with rimonabant resulted in reduced angiotensin II-mediated but not basal ROS production and NADPH oxidase activity. CB(1)-R inhibition with rimonabant and AM251 led to down-regulation of angiotensin II type 1 receptor (AT1-R) expression, whereas stimulation with the CB(1)-R agonist CP 55,940 resulted in AT1-R up-regulation, indicating that AT1-R expression is directly regulated by the CB(1)-R. CB(2)-R inhibition had no impact on AT1-R expression in VSMC. Consistently, CB(1)-R inhibition decreased aortic AT1-R expression in vivo. CB(1)-R inhibition leads to decreased vascular AT1-R expression, NADPH oxidase activity and ROS production in vitro and in vivo. This antioxidative effect is associated with improved endothelial function in ApoE-/- mice, indicating beneficial direct vascular effects of CB(1)-R inhibition.
Authors:
Vedat Tiyerili; Sebastian Zimmer; Suzin Jung; Kerstin Wassmann; Claas P Naehle; Dieter Lütjohann; Andreas Zimmer; Georg Nickenig; Sven Wassmann
Related Documents :
10221757 - Modification of 5-ht2 receptor mediated behaviour in the rat by oleamide and the role o...
18220777 - Cannabinoids and neuroprotection in motor-related disorders.
11224447 - Opposing effects of cck(a) and cck(b) antagonists on the development of conditioned act...
11861807 - A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hy...
9203417 - Natural killer cell receptors.
1325237 - Adrenalectomy and stress modulate gabaa receptor function in ls and ss mice.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-04-02
Journal Detail:
Title:  Basic research in cardiology     Volume:  105     ISSN:  1435-1803     ISO Abbreviation:  Basic Res. Cardiol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-05-04     Completed Date:  2010-08-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0360342     Medline TA:  Basic Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  465-77     Citation Subset:  IM    
Affiliation:
Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, Bonn, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Apolipoproteins E / deficiency
Atherosclerosis / metabolism*
Cells, Cultured
Endothelium, Vascular / physiology*
Female
Mice
Mice, Inbred C57BL
Mice, Knockout
Oxidative Stress*
Piperidines
Pyrazoles
Rats
Rats, Sprague-Dawley
Receptor, Angiotensin, Type 1 / metabolism*
Receptor, Cannabinoid, CB1 / antagonists & inhibitors,  metabolism*
Chemical
Reg. No./Substance:
0/Apolipoproteins E; 0/Piperidines; 0/Pyrazoles; 0/Receptor, Angiotensin, Type 1; 0/Receptor, Cannabinoid, CB1; 158681-13-1/rimonabant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency: preva...
Next Document:  TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheime...